New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:45 EDTPRGO, MYLMylan would be a good target for Perrigo, dealReporter says citing source
A banker considers Mylan a good target for Perrigo and believes the company is reconsidering big deals, says dealReporter.
News For PRGO;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 17, 2015
14:23 EDTPRGO, MYLMylan jumps after Dow Jones says Teva considering bid
Subscribe for More Information
14:21 EDTMYLTeva weighing potential bid for Mylan, Dow Jones says
Subscribe for More Information
12:56 EDTMYLFederal Circuit upholds Mylan's patents on Perforomist inhalation solution
Mylan (MYL) announced the United States Court of Appeals for the Federal Circuit upheld the validity and infringement of all four patents asserted by Mylan Specialty, L.P. protecting its Perforomist Inhalation Solution. The Court summarily affirmed the previous decision by the district court against Teva (TEVA). Today's decision prevents Teva from receiving final approval of its ANDA from the FDA prior to expiration of U.S. Patent Nos. 6,667,344; 6,814,953; 7,348,362; and 7,462,645. Those patents cover Perforomist until they expire in June 2021.
08:00 EDTMYLTeva patent loss should move management to acquire Mylan, says Cowen
Subscribe for More Information
05:53 EDTMYLStocks with implied volatility movement; XLNX MYL
Subscribe for More Information
April 16, 2015
15:40 EDTMYLGeneric Copaxone approval a bit early but expected, says BMO Capital
BMO Capital believes FDA approval for Sandoz (NVS) and Momenta's (MNTA) generic 20mg Copaxone came slightly earlier than the market expected, but the firm added that the generic threat has been well expected. The firm added that it appears Mylanís (MYL) generic Copaxone hasn't been approved yet, leaving a "legitimate question" about why the FDA approved one generic and not the other. BMO thinks Teva's rate of conversion to the 40mg dose will help retain patients on the Copaxone franchise and it keeps an Outperform rating on Teva shares.
14:12 EDTPRGOPerrigo announces launch of generic version of Kenalog nasal spray
Subscribe for More Information
10:15 EDTPRGOOptions with decreasing implied volatility
Subscribe for More Information
April 15, 2015
09:02 EDTMYL, PRGORBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
06:09 EDTPRGOStocks with implied volatility below IV index mean; FXE PRGO
Subscribe for More Information
April 14, 2015
10:50 EDTPRGOOptions with increasing implied volatility
Subscribe for More Information
April 13, 2015
15:12 EDTMYLMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.
10:48 EDTPRGOOptions with increasing implied volatility
Options with increasing implied volatility: CLDN WETF EWH FOSL FXI TLM PRGO ATHN SYMC MAC
07:56 EDTMYL, PRGOMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
06:49 EDTMYL, PRGOMylan notifies Perrigo of HSR filing regarding proposed acquisition
Mylan N.V. (MYL) announced that it has provided Perrigo (PRGO) with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.
April 10, 2015
16:19 EDTPRGO, MYLStocks finish week higher as investors speculate jobs data could delay rate hike
Subscribe for More Information
11:30 EDTMYLStocks with call strike movement; MSFT MYL
Microsoft (MSFT) October 48 call option implied volatility increased 9% to 38, Mylan (MYL) July 85 call option implied volatility decreased 11% to 31 according to IVolatility.
10:00 EDTPRGOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:29 EDTMYLMylan price target raised to $80 from $66 at Argus
Argus hiked its price target on Mylan (MYL) after the company announced a non-binding proposal to acquire Perrigo Co. (PRGO) for $205 per share. The firm remains upbeat on the outlook for generic drugs in general, and says that generic over-the-counter pharmaceuticals, an area of focus for Perrigo, are rapidly taking share from brand-name OTC products. The firm keeps a Buy rating on Mylan
08:20 EDTPRGOPerrigo downgraded to Hold from Buy at Argus
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use